Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombin in sepsis revisited.

Marcel Levi1

  • 1Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. m.m.levi@amc.uva.nl

Critical Care (London, England)
|December 17, 2005
PubMed
Summary

Antithrombin concentrate did not improve 28-day mortality in severe sepsis patients. However, new data on coagulation effects and restored anticoagulant pathways may renew interest in antithrombin for sepsis treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial intelligence in diagnostics and medical decision making.

European journal of internal medicine·2026
Same author

Response to the comment by Gando on the updated definition and scoring of disseminated intravascular coagulation.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Laboratory and Medicine 2.1: Care for What You Wish for.

International journal of laboratory hematology·2026
Same author

Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Organ Dysfunction in Sepsis-associated Intravascular Coagulation.

Juntendo Iji zasshi = Juntendo medical journal·2024
Same author

Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?

Journal of thrombosis and haemostasis : JTH·2024

Area of Science:

  • Critical care medicine
  • Hematology
  • Pharmacology

Background:

  • Pivotal phase III trials found no significant benefit of antithrombin concentrate on 28-day mortality in severe sepsis.
  • This outcome led to diminished interest in antithrombin as a sepsis treatment modality.

Discussion:

  • Recent data suggest antithrombin administration impacts coagulation in sepsis patients.
  • Re-analysis of clinical trials focusing on restoring physiological anticoagulant pathways may offer new perspectives.

Key Insights:

  • Antithrombin's role in severe sepsis warrants re-evaluation.
  • Coagulation modulation is a key consideration in sepsis treatment.

Outlook:

  • Further research may explore specific patient subgroups or treatment protocols for antithrombin in sepsis.
  • Investigating the interplay between antithrombin, coagulation, and sepsis pathophysiology is crucial.

Related Experiment Videos